Expression of TYRO3 has been noted in a variety of malignancies, including colon cancer [35,36], breast cancer [37,38,39,40], lung cancer [41,42,43,44], liver cancer [33,45,46], thyroid cancer [47], melanoma [48,49,50,51,52,53], schwannoma [54,55], ovarian cancer [56,57,58], prostate cancer [59,60], leiomyosarcoma [61,62], dedifferentiated liposarcoma [61], undifferentiated pleomorphic sarcoma [61], synovial sarcoma [61], esophageal cancer [63], endometrial cancer [64], multiple myeloma [65] and several leukemia subtypes [66,67,68]. Here, TYRO3 is linked to prostate carcinoma.